InvestorsHub Logo
icon url

iwasadiver

08/09/21 9:39 PM

#394604 RE: JerryCampbell #394603

You’re overthinking this. Clinical trials are constantly reporting results in the face of new technologies that appear to have significant impact on survival. But until that other entity is reporting P3 data they’re not a threat or a factor. NWBO has data that is way beyond the P3 trial they just did, and it will be the basis of everything they do strategically going forward. it’s that attitude and foresight that will, in my opinion, make this a $100-200 stock in as little as 2 years.

Any astute investor who’s retail has seen and captured this. The big Funds know it also and are simply waiting for the signal they need to start buying in earnest. TLD will unleash the flood of money on the sidelines who know what’s coming. They have the money in the account, just waiting to hit the button. It’s a foregone conclusion in the business.
icon url

Dr Bala

08/09/21 9:39 PM

#394605 RE: JerryCampbell #394603

LL's presentation has the curves for the ECAs and they are all bunched together, i.e, no significant improvement for one ECA over another. So, not a problem.

See slides numbered 19 and 20 in the pdf link.

https://www.dr-bala.net/NWBO/Liau_MtSinai_20210519.pdf
icon url

flipper44

08/09/21 9:48 PM

#394607 RE: JerryCampbell #394603

NWBO is also comparing treatment to placebo. I’d think you and ex wouldn’t have to be told that nine billion times.

I think it’s as simple as “better” and “even better.” There were a couple Doctors using 5-ala in the U.S. at the time of trial as well. I think Dr. Sloan was a strong advocate.

Remember, 5-ala with current SOC does not significantly improve matters.
icon url

biosectinvestor

08/09/21 9:51 PM

#394609 RE: JerryCampbell #394603

Surgical improvements…do not ultimately prevent recurrence without an additional treatment to get the impossible to resect, or invisible / microscopic tumor tissue. This is a fast growing cancer and there is no real evidence that without an additional treatment that there is substantial extension of survival.

It is clearly important to reduce such tissue so that additional treatments can get the remainder, but I highly doubt that any of the top doctors, and this is largely being led by top surgeons, would agree with you.

Additionally, the mere existence of pseudoprogression and signs of inflammation suggest you’re not discussing the topic accurately.